Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer
This study will determine the feasibility and toxicity of a short course of accelerated
radiotherapy as adjuvant treatment for early stage breast cancer. Successful completion of
this project may provide a rationale to offer this treatment for select patients with the
benefit of potentially less tissue damage and a shorter overall course of therapy. These
improvements may ultimately allow more patients the opportunity of breast conserving therapy
to treat their cancer
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the feasibility of using CyberKnife radiotherapy to deliver partial breast radiotherapy for early stage breast cancer.
Subjects will undergo a treatment plan for partial breast irradiation with cyberknife. Feasibility will be determined by monitoring the number of potential eligible subjects enrolled that can be treatedwhile also respecting normal tissue tolerances.
Ken Dornfeld, MD
Essentia Health Oncology
United States: Food and Drug Administration
|Essentia Health SMDC Cancer Center||Duluth, Minnesota 55805|